Physician profile
John B Townsend
NPI 1982656245
$883.07
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $674 · 2020: $210.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $172.15 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $112.78 | 2019 | |
| Alexion Pharmaceuticals, INC. | $103.24 | 2019-2020 | |
| Biogen, INC. | $65.98 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $61.15 | 2019 | |
| Shire North American Group INC | $57.81 | 2019 | |
| Lilly USA, LLC | $52.14 | 2019-2020 | |
| Genzyme Corporation | $50.15 | 2019 | |
| Emd Serono, INC. | $40.32 | 2019 | |
| Arbor Pharmaceuticals, INC. | $38.00 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $30.46 | 2019 | |
| Tanabe Pharma America, INC. | $22.56 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.96 | 2020 | |
| Harmony Biosciences LLC | $16.39 | 2020 | |
| Zyla Life Sciences, INC. | $15.47 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $13.60 | 2019 | |
| Allergan, INC. | $12.91 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Townsend listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.